United Therapeutics Corporation (UTHR) Receives Analyst Rating

United Therapeutics Corporation (UTHR) : 8 analysts are covering United Therapeutics Corporation (UTHR) and their average rating on the stock is 2.5, which is read as a Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 6 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

United Therapeutics Corporation (UTHR) has been rated by 8 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $229 and the lowest price target forecast is $95. The average forecast of all the analysts is $134.63 and the expected standard deviation is $40.26.


Also, JP Morgan maintains its view on United Therapeutics Corporation (NASDAQ:UTHR) according to the research report released by the firm to its investors. The shares have now been rated Neutral by the stock experts at the ratings house. JP Morgan lowers the price target from $145 per share to $129 per share on United Therapeutics Corporation. The rating by the firm was issued on July 29, 2016.

United Therapeutics Corporation (NASDAQ:UTHR): After opening at $122.3, the stock dipped to an intraday low of $120.44 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $123.285 and the buying power remained strong till the end. The stock closed at $122.78 for the day, a gain of 0.20% for the day session. The total traded volume was 495,520. The stocks close on the previous trading day was $122.53.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin, Tyvaso (treprostinil), Adcirca (tadalafil), Remodulin Implantable System, Orenitram Combination Therapy, Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb, for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation, for the treatment of End-stage lung disease; UV-4B, for the treatment of Dengue and influenza, and Glycobiology Antiviral Agents, for the treatment of a spectrum of agents against viral infectious diseases, among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.